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Background: New Zealand and Australia have the highest incidence and mortality rates from cutaneous melanoma
in the world. The predominantly fair-skinned New Zealanders and Australians both enjoy sun, tanned skin and the
outdoors, and differences in these activities among generations have been important determinants of trends in
melanoma mortality.
We examined whether New Zealand trends in melanoma mortality mirror those in Australia, through detailed
comparison of the trends in both countries from 1968 to 2007.
Methods: Five-year age-specific and age-standardised mortality rates were calculated for each country for 5-year
time periods. Tests for trends in age-specific rates were performed using the Mantel-Haenszel extension chi-square
test. The age-adjusted mortality rate ratios for New Zealand/Australia were plotted against period of death to show
relative changes in mortality over time. Age-specific mortality rates were plotted against period and the median
year of birth to illustrate age-group and birth cohort effects. To compare the mortality of birth cohorts, age-
adjusted melanoma mortality rate ratios were calculated for the birth cohorts in the quin-quennial tables of
mortality rates.
Results: The age-standardised mortality rate for melanoma increased in both sexes in New Zealand and Australia
from 1968 to 2007, but the increase was greater in New Zealanders and women in particular. There was evidence
of recent significant decreases in mortality in younger Australians and less so in New Zealand women aged under
45 years. Mortality from melanoma increased in successive generations born from about 1893 to 1918. In Australia,
a decline in mortality started for generations born from about 1958 but in New Zealand there is possibly a decrease
only in generations born since 1968.
Conclusions: Mortality trends in New Zealand and Australia are discrepant. It is too early to know if the pattern in
mortality rates in New Zealand is simply a delayed response to melanoma control activities compared with
Australia, whereby we can expect the same downward trend in similar age groups in the next few years. Specific
research is needed to better understand and control the increases in mortality and thickness of melanoma in New
Zealand.
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New Zealand and Australia have the dubious distinction
of having the highest incidence rates of and mortality
rates from cutaneous melanoma in the world [1]. In
2007 in New Zealand, from a total population of 4 mil-
lion people, 2,173 people were registered with melanoma
and 292 people died from the disease [2], whereas in
Australia, a country of 21 million inhabitants, 10,342
people were diagnosed with melanoma and 1,279 died
from it [3].
The major modifiable risk factor for melanoma is
exposure of the skin to UV radiation, with total dose
determined by both ambient UV and personal behaviour.
New Zealand and Australia have high levels of ambient
UV radiation. The major Australian cities range in lati-
tude from Darwin (12.3°S) to Hobart (42.5°S), with sum-
mer UV indices (where 1 UV Index unit = 25 mW/m2)
[4] ranging between 15 and 11. New Zealand has a range
of latitude from Kaitaia (35°S) to Bluff (46°S), with sum-
mer UV indices from 13 to 8. An overall trend of de-
creasing melanoma incidence with increasing latitude
occurs in both countries.
Melanoma incidence and mortality rates have been ris-
ing among white populations world-wide for many years
[5] stimulating the development of public health policies
encouraging reduced exposure to the sun. Promotion of
sun-safety messages started in some Australian states in
the 1960s [6,7]: the first large-scale programme started in
1980 [8]. In New Zealand the first skin cancer preven-
tion campaign started in the mid-1980s, and in 1987 this
changed to a greater emphasis on melanoma specific
prevention [9].
The predominantly fair-skinned New Zealanders and
Australians share a liking for sun, tanned skin and out-
door activities and it has been suggested that differences
in these activities among generations of Australians and
New Zealanders have been important determinants of
the trends in melanoma mortality [10,11]. In some coun-
tries, including Australia, these trends in incidence and
mortality may be changing and a decreasing risk of melan-
oma for more recent generations in some countries has
been observed [7,12,13]. For many years New Zealand has
relied on importing Australian sun protection activities
and Australian skin cancer research to guide its health
promotion and policy direction on the assumption that its
melanoma trends would mirror those in Australia. To
assess the accuracy of this supposition, we conducted a
detailed comparison of the melanoma mortality trends in
Australia and New Zealand using routinely collected data
from 1968 to 2007.
Methods
The annual numbers of deaths from melanoma from 1968
to 2007 and mean annual total population estimates wereobtained from publications of the New Zealand Ministry
of Health [14,15] and, for Australia, equivalent data were
obtained from the Australian Institute of Health and
Welfare (http://www.aihw.gov.au). Registration of death
has been compulsory in New Zealand and Australia
throughout the time period studied and both countries
have coded cause of death to the relevant International
Statistical Classification of Diseases and Related Health
Problems. In Australia the Australian Institute of Health
and Welfare provides reliable, regular and relevant infor-
mation and statistics on Australia’s health and welfare [3].
In Australia, deaths are registered by the Registrars of
Births, Deaths and Marriages in each State and Territory
and since 1906 the Bureau of Census and Statistics has
compiled the information collected by the Registrars and
published national death statistics [16].
As 2007 is the most recent year for which suitably de-
tailed published data for mortality by sex and age-group
are available in Australia, data for New Zealand were re-
stricted to the same period. Since death from melanoma
is rare in children, only deaths occurring in people aged
15 years or more were included in the analysis.
Statutory notification of pathology reports of cancer in
New Zealand was not introduced until 1 July 1994, and
the introduction had a major impact on the reporting of
melanoma, resulting in insufficient years of complete
data available for a similar comparison of melanoma in-
cidence between the two countries. Therefore this paper
is restricted to a comparison of melanoma mortality.
Five-year age-specific mortality rates were calculated for
both countries over successive 5-year time periods. Age-
standardised rates were calculated using Segi’s world
standard population [17]. Statistical tests for trends in age-
specific rates, tests for the overall trend and non-linearity
of any trend were performed using the Mantel-Haenszel
extension chi-square test [18]. Age-specific rates for both
countries were plotted to show the contour of melanoma
mortality over various times and age groups for each sex.
The age-adjusted mortality rate ratios for New Zealand/
Australia were plotted against period of death to show
relative changes in mortality trends over time, and age-
specific mortality rates were plotted against period and the
median year of birth to illustrate age-group and birth co-
hort effects [19]. For comparisons of the melanoma mor-
tality experience of birth cohorts between the countries,
age-adjusted melanoma mortality rate ratios were calcu-
lated over the age groups available for the birth cohorts
represented in the quin-quennial tables of mortality rates.
Results
Between 1968 and 2007, 6,721 New Zealanders and
29,825 Australians died from melanoma. In New Zealand
in 2007 the age-standardised mortality rates (ASMR) for
melanoma for men and women were 6.4 and 3.4 per
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people, 178 men and 114 women died from the disease. In
Australia in 2007, a country of 21 million inhabitants, 864
men and 415 women died from melanoma with an ASMR
of 5.8 per 100,000 for men and 2.5 per 100,000 for
women.
The contour graphs for age, period of death, and mel-
anoma mortality rate for New Zealand and Australian
men are shown in Figure 1 and for women in Figure 2.
These represent the surface of melanoma mortality for
the population during the years 1968–2007 in five-year
age groups. The surfaces demonstrate the pronounced
increase in mortality since the 1970s, particularly in
older age groups, for both men and women in Australia
and New Zealand. Melanoma mortality was higher in
New Zealand than in Australia in the most recent years,
particularly at older ages, for both men and women. The
determinants of mortality that govern these surfaces in-
clude age effects (increased mortality with age), gener-
ational or cohort effects (experiences of risk or protective
factors for the lifetime of each generation included), and
period effects (for example, changes in risk factors, stage
at presentation, melanoma subtype, or treatments that
have occurred across all age groups in particular time
periods).
Comparison by period of death
From 1968 to 2007 the age-standardised mortality rate
for melanoma increased in both New Zealand and
Australian men (see Additional file 1: Table S1), but
more so in New Zealand men (Figure 3). During the
years 1968–1997 mortality rates for melanoma were very
similar in New Zealand and Australian men (age-adjusted
mortality rate ratios ranged from 0.99 to 1.07), but in
1998–2002 and 2003–2007 the mortality rates in New
Zealand men were significantly higher than in Australian
men. Among women the pattern of mortality rates was
somewhat different. Although the mortality rates from







































































Age group in years
Time period
(a) New Zealand melanoma mortality for men
Figure 1 Contour surfaces of male melanoma mortality for (a) New Z1968–1972 (see Additional file 1: Table S2), they increased
more in New Zealand women and considerably earlier
than occurred for men. From 1973–1977 all mortality
rates in New Zealand women were significantly higher
than Australian women, and by 2003–2007 New Zealand
women had a 40% higher melanoma mortality rate com-
pared to Australia (Figure 3).
Comparisons by period of death and age group
As the time trends in mortality were significantly hetero-
geneous (p < 0.001) with age group for each sex, the
overall age-standardised rates conceal important and di-
vergent age-specific trends in both countries.
In New Zealand from 1968–72 to 2003–07 (Figure 4)
no statistically significant reduction in melanoma mortal-
ity occurred in men 15–34 years (p = 0.26) or 35–44 years
of age (p = 0.88), while over the same time significant
increases were observed for men 45–64 years (p < 0.001)
and 65 or more years of age (p < 0.001). In contrast in
Australia (Figure 4), significant decreases in melanoma
mortality occurred in men 15–34 and 35–44 years of
age (p < 0.001 for both), whereas mortality significantly
increased for men 45 or more years of age (p < 0.001).
The trends over time were significantly non-linear for
Australian and New Zealand men 45–64 years of age.
From 1968–72 to 2003–07 in New Zealand, melan-
oma mortality significantly decreased in women 15–34
(p = 0.009) and 35–44 years of age (p = 0.04; Figure 5),
with no significant change in women 45–64 years of
age, and increased in women 65 or more years of age
(p < 0.001). However, in Australia over the same time,
female melanoma mortality has decreased significantly
in the 3 youngest age groups (15–34 years, p < 0.001;
35–44 years, p < 0.001; and 45–64 years, p = 0.008), but
increased significantly for women 65 or more years of
age (p < 0.001).
In the 2003–07 time period the increase in melanoma
mortality with age for men was very similar in both
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(b) Australian melanoma mortality for men
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Age group in years
Time period
(b) Australian melanoma mortality for women 
Figure 2 Contour surfaces of female melanoma mortality for (a) New Zealand and (b) Australia.
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was higher than in Australia by between 24% and 69%,
with statistically significant higher mortality for women
aged 40–44, 70–74, and 80 or more years of age (see
Additional file 1: Table S2).
Comparison by birth cohort
The New Zealand age-specific melanoma mortality rates
by birth cohort (identified by their median year of birth)
for both sexes combined are shown in Figure 6. Melanoma
mortality increased in each generation born from about
1893 until 1918. For New Zealanders born after 1968
there appeared to be a decrease in mortality rates, but
death from melanoma was infrequent in these most recent
birth cohorts due to their young age. A similar graphical
representation of age-specific mortality rates by birthFigure 3 Rate ratios for age-standardised melanoma mortality: New Z
is marked.cohort in both sexes combined is shown for Australia in
Figure 7. Mortality from melanoma in Australia increased
successively for each generation until those born about
1923. Then for people born since 1958, their mortality
from melanoma tended to decline.
Male mortality rate ratios for these birth cohorts (see
Additional file 1: Table S1) indicated that New Zealand
melanoma mortality has been significantly higher than
in Australia for men born about 1933 to 1948 and
about 1968. New Zealand women born about 1888,
1913 to 1948, and 1958 to 1963 also had significantly
higher mortality than their Australian equivalents (see
Additional file 1: Table S2). No New Zealand birth
cohort for either men or women had significantly
lower mortality than the corresponding Australian
birth cohort.ealand/Australia. The line of equal mortality rates (rate ratio = 1)
Figure 4 Trends over time in melanoma mortality for New Zealand and Australian men by age group. (y-axis on log scale).
Figure 5 Trends over time in melanoma mortality for New Zealand and Australian women by age group. (y-axis on log scale).
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Figure 6 New Zealand melanoma mortality by 5-year age group and median year of birth. Both sexes combined. (y-axis on log scale).
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The data for this population-based study came from
routinely collected and published death statistics for
Australia and New Zealand. Melanoma is a common
cancer in both countries, and as certification and coding
of causes of death are very similar in Australia and New
Zealand and follow international guidelines [20,21] a sys-
tematic difference in accuracy of cause of death between
the two countries is unlikely. Furthermore, systematicFigure 7 Australian melanoma mortality by 5-year age group and medifferences in determination and recording of cause of
death are likely to be small as physicians in New Zealand
and Australia are all trained by the Royal Australasian Col-
lege of Physicians. Under-reporting of melanoma mortality
would have to be systematically different for each sex to
account for the differences in mortality rates observed,
which we consider unlikely.
Similarities in the overall approach to melanoma control
in New Zealand and Australia provided an opportunity todian year of birth. Both sexes combined. (y-axis on log scale).
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population-based study of mortality from melanoma it
was shown that although the age-standardised mortality
rate for melanoma had increased in both sexes in New
Zealand and Australia from 1968 to 2007, the increase in
mortality was greater in New Zealanders and New Zealand
women in particular. Within these overall increases there
was evidence of recent decreases in mortality in younger
Australian men and women, and to a lesser degree in New
Zealand women aged less than 45 years. Examination of
the cohort curves suggested that the increasing mortality
in each age group over time was not an effect due to
increased age alone, but was also affected by the ageing
of generations with higher mortality rates throughout
their lives.
It has been previously shown that in New Zealand,
overall melanoma mortality increased consistently from
1949 to 1989 predominantly due to birth cohort effects
[22]. In women the rates increased approximately
linearly over this time whereas in men the rates increased
much more rapidly in the second half of the period. An
Australian study of annual melanoma mortality diagnosed
from 1931 to 2002 found that mortality rates peaked about
1985, significantly decreased after 1985 in people aged
under 55 years and stabilized at 55–79 years of age [23].
In many geographic regions with intermediate or low rates
of melanoma, such as England and parts of Europe, mor-
tality from melanoma has begun to level off or decline in
more recent birth cohorts but this is not universal [24-27].
In Scotland, mortality in young people is still increasing
[28] and melanoma mortality in younger US men also
increased from 1990 to 2007 [29].
The prevention of death from melanoma is not as effect-
ive in New Zealand as in Australia, but the reasons for this
are unknown. It is too early to know if the pattern in mor-
tality rates in New Zealand is simply a delayed response
compared with Australia whereby we can expect the same
downward trend in similar age groups in the next few
years, or if New Zealand’s melanoma mortality is on a
different trajectory, or a combination of both. Although
there is some evidence that mortality in New Zealanders is
decreasing in recent generations, men and women born
from 1963 to 1968 still experience significantly higher
mortality in New Zealand than Australia and it is import-
ant to investigate the possible reasons for this.
As survival and mortality from melanoma depend pre-
dominantly on thickness at diagnosis (the treatment for
melanoma having remained unchanged for many years),
the differences in mortality between Australia and New
Zealand could be due to differences in the thickness of
melanomas at diagnosis: the thickness of melanoma at
diagnosis has been increasing in New Zealand for more
than a decade [30]. For this to occur, either the presenta-
tion of melanoma is different, or techniques have beenused in the past that allow earlier diagnosis in Australia,
or in New Zealand there is greater delay prior to diagnosis
and/or treatment, or the distribution of melanoma sub-
types (with dissimilar depth distributions) differ between
the two countries.
Improving early detection is an obvious way forward
and is likely to result in reductions in mortality more
quickly than preventive campaigns [31]. It is possible
that the New Zealand public has not recognised suspi-
cious skin lesions as well as Australians and therefore
not presented them to health services early enough in
their natural history. Approximately half the melanomas
detected in Queensland (Australia) and New Zealand
were first noticed by the patient and the reported signs
and symptoms were very similar [32,33]. For layperson-
detected melanomas, over half were noticed first because
of a change in colour followed by a change in size, and
although itchiness is not a major warning sign of melan-
oma, 13.2% of patients in Australia and 12.4% in New
Zealand said that their lesion was itchy. New Zealanders
reported slightly fewer pale or colourless lesions than in
Australia (3.5% and 5.3%, respectively) so the proportion
of amelanotic lesions, which are less likely to be recog-
nized as suspicious of melanoma, has not contributed to
the poorer mortality rates in New Zealand.
Another possibility is that clinicians in Australia diag-
nosed melanoma earlier than in New Zealand resulting in
a better prognostic depth distribution. However, historical
evidence does not support this: national Australian data
for 1990 to 2006 showed that 62.7% of invasive melano-
mas diagnosed were thin (<=1.0 mm) and 5.1% were
thick (>4.0 mm) [34], similarly, in New Zealand from
1996–2007 63.6% were thin and 7.3% were thick. Fur-
thermore, from 1990–2006 Australian melanoma inci-
dence rates increased in all thickness categories. In the
early 1990s in Australia, the increase in thin melanomas
was approximately double that of thick melanomas but
these increasing trends in thin melanomas have plat-
eaued since 1996. In New Zealand the rate of increase
in incidence was greatest in melanomas >1 mm thick
and since 1996 the median melanoma thickness has in-
creased [30]. The degree to which these trends are due
to delays in diagnosis and treatment are unknown.
Internationally no association has been found between
the thickest tumours and patient or physician delay,
[35-38] rather, it is probable that the greater thickness
can be accounted for by more aggressive, rapidly growing
lesions [30].
Melanoma subtypes are known to have widely varying
depth distributions, with nodular and acral melanomas
usually being thickest at diagnosis. In 2000–2003 in
Queensland Australia, nodular melanoma accounted for
8% of all invasive melanomas but 38% of melanomas
thicker than 2.0 mm [39]. In New Zealand between 1996
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sive melanomas but only 26.8% of melanomas thicker than
2.0 mm: the greatest percentage of melanomas >2 mm
thick (45.1%) were classified as melanoma with no morph-
ology recorded.
High skin cancer incidence and mortality rates in
Australia and New Zealand have stimulated the develop-
ment of public health policies for skin cancer prevention
which aim to encourage decreased exposure to sun
through a number of personal protective and avoidance
measures [8]. The first large-scale sun safety programme
‘Slip! Slop! Slap!’ started in Australia in 1980 [8] followed
by SunSmart from 1988 [6]. For about 30 years the
programmes have been hosted by a stable and support-
ive organization and had adequate and reliable funding,
without which it is difficult to sustain momentum for a
lasting impact [6]. In New Zealand the first skin cancer
prevention campaign, also ‘Slip! Slop! Slap!’ started in the
mid-1980s but this changed in 1987 to a more focused
message on melanoma prevention [9]. It is difficult to de-
termine the impact of these campaigns on melanoma inci-
dence, but any postulated beneficial effect on melanoma
mortality has not been pronounced. Without substantial
improvements in treatment, improvement in mortality re-
lies on a decrease in the incidence of thick melanomas,
not just thin melanomas. However, thus far, the incidence
of thick melanomas has not decreased in New Zealand
and any possible beneficial effect would appear to have
been greater in Australia.
Conclusions
The points raised highlight the need for the collection of
more detailed and accurate data on melanoma and much
more research to explain the differing mortality trends
found between the Australian and New Zealand popula-
tions. Specifically, future research should address the fol-
lowing questions: Is the diagnosis of melanoma made
earlier in the natural history of the disease in Australia?
Is the stage and thickness at presentation of melanoma
subtypes later in New Zealand? Are subtype distributions
contributing to differences in mortality? This study also
identifies a need to expand New Zealand-based research
in order to achieve greater understanding and subsequent
control of the increases in mortality and thickness of
melanoma in New Zealand.
Additional file
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and rate ratios for New Zealand and Australian men. Table S2.
Melanoma age-standardised mortality rates and rate ratios for New
Zealand and Australian women.
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